Sri International

Boston University

University of Pittsburgh

Medical University of South Carolina

Tony Tianyi Wang

Shufeng Liu

John A Porco, Jr

Neil Lajkiewicz

Wenhan Zhang

Fan Daping

Wenyu Wang

Described herein are compounds, agents, compositions, and methods related to the treatment of a viral infection (e.g., Hepatitis C viral infection). In particular, the compounds, agents, compositions, and methods described herein inhibit viral entry into a target cell.

Compositions and methods for inhibiting viral infection

Disclosed herein are several apoplipoprotein E (ApoE) polypeptides, and nucleic acids encoding these polypeptides, that can be used to treat or prevent a hepatitis infection in a subject, such as a hepatitis C virus infection. These ApoE polypeptides can inhibit the entry of hepatitis C virus into cells, and inhibit viral replication. Nucleic acids encoding these polypeptides are also disclosed, as well as methods.

Apolipoprotein E polypeptides and their use

A rocaglamide or a rocaglate derivative, particularly aglaroxin C, blocks hepatitis C virus (HCV) entry with improved potency and therapeutic index.

Aglaroxin C and derivatives as HCV entry inhibitors

Growing community of inventors

Harrisonburg, VA, United States of America

Tony Tianyi Wang